1,2-bis(phenylseleno)ethane | 37183-13-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-bis(phenylseleno)ethane
• 英文别名: 1,2-bis(phenylselanyl)ethane；1,2-Diphenylselenoethane；2-phenylselanylethylselanylbenzene
• CAS: 37183-13-4
• 化学式: C₁₄H₁₄Se₂
• 分子量: 340.185
• InChiKey: GHYZSEHNKPNUJM-UHFFFAOYSA-N

物化性质

• 沸点：
  399.0±38.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.88
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1,2-bis(phenylseleno)ethane 以 乙醇 、 乙二醇甲醚 为溶剂， 生成 tetraethylammonium {1,2-bis(phenylseleno)ethane}tetrabromoiridate(III)
  参考文献：
  名称：

  较高氧化态的配位化学。第27部分。某些顺式-四卤代铱（IV）配合物的合成，性质和电化学：[Ir（phen）Cl 4 ]的晶体结构

  摘要：

  铱（IV）络合物为顺式-[Ir（L–L）Cl 4 ] [L–L = MeSCH 2 CH 2 SMe，MeSeCH 2 CH 2 SeMe，2,2'-联吡啶（bipy）或1,10-菲咯啉（phen）是通过Cl 2或HNO 3氧化相应的Ir III阴离子[Ir（L–L）Cl 4 ] –制备的。还描述了深绿色的顺式-[Ir（L-L）Br 4 ]（L = L = bipy或phen）和顺式-[Ir（py）2 X 4 ]（X = Cl或Br）。铱（III）配合物[Ir {RTe（CH 2）3 TeR} Cl 4 ] –（R = Me或Ph），[{Ir [Me 2 Sb（CH 2）3 SbMe 2 ] Cl 3 } n ]，反式-[Ir（L–L）2 Cl 2 ] + [L–L = Ph 2 PCH 2 CH 2 PPh 2（dppe），Me 2 PCH 2 CH 2 PMe 2（dmpe）或o -C

  DOI：

  10.1039/dt9880002483
• 作为产物：
  描述：

  二苯二硫醚 在 hydrazine hydrate 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 3.0h， 生成 1,2-bis(phenylseleno)ethane
  参考文献：
  名称：

  Nucleophilic Cleavage of the Ether Bond of Chlorex in the Chalcogenation with Diphenyl Dichalcogenides in the System Hydrazine Hydrate–KOH

  摘要：

  The synthesis of unsymmetrical pincer ligands by reactions of diphenyl disulfide and diphenyl diselenide with bis(2-chloroethyl) ether in the system hydrazine hydrate-KOH was accompanied by the formation of 1,2-bis(phenylsulfanyl)ethane, 1,2-bis(phenylselanyl)ethane, and 1-(phenylselanyl)-2-(phenylsulfanyl)ethane as by-products with an overall yield of 23% as a result of nucleophilic cleavage of the C-O-C bond in the initial ether.

  DOI：

  10.1134/s1070363220090273

文献信息

• [EN] RHENIUM COMPLEXES AND THEIR PHARMACEUTICAL USE.<br/>[FR] COMPLEXES DE RHÉNIUM ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：COORDINATION DE RECH S THERAPEUTIQUES SOC D

  公开号：WO2011151399A1

  公开（公告）日：2011-12-08

  The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m = 0, 1, or 2 and p = 0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n = 3; R' is a phenyl group or a group of general Formula -(CH2)q-COOH wherein q = 1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex where X is additionally S or Te, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex where X is additionally S or Te. Also claimed is the use of compounds of formula (II) in the preparation of compounds of formula (I).

  本发明涉及一个通式（I）的钌配合物，或其药用可接受的盐或溶剂化物，其中X是Se；Y是NH、O或S，或者是一个亚甲基基团；Z是卤素；m=0、1或2，p=0、1或2，前提是当Y是NH、O或S时，m和p都不为零；n=3；R'是一个苯基团或一个通式为-(CH2)q-COOH的基团，其中q=1或2，一种药物组合物，包含治疗有效量的至少一种这样的钌配合物，其中X另外还是S或Te，一种制备所述钌配合物的方法，以及一种使用治疗有效量的至少一种所述钌配合物治疗增生性生长相关疾病的方法，其中X另外还是S或Te。还声称了化合物公式（II）在制备化合物公式（I）中的用途。
• Rhenium complexes and their pharmaceutical use
  申请人：SOCIETE DE COORDINATION DE RECHERCHES THERAPEUTIQUES

  公开号：EP2392324A1

  公开（公告）日：2011-12-07

  The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof wherein X is chosen from S Se or Te; Y is NH, O or S or is a methylene group; Z is halogen; m = 0,1 , or 2 and p = 0,1 , or 2, provided that m and p are both different from zero when Y is NH, O or S; n = 3; R1 is a phenyl group or a group of general Formula (CH2)q-COOH wherein q = 1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex. Also claimed are compounds of formula (II).

  本发明涉及一种通式(I)的钌配合物，或其药用可接受的盐或溶剂化物，其中X选自S、Se或Te；Y是NH、O或S，或是一个亚甲基基团；Z是卤素；m=0,1或2，p=0,1或2，前提是当Y是NH、O或S时，m和p都不为零；n=3；R1是一个苯基团或一个通式为(CH2)q-COOH的基团，其中q=1或2，一种包含至少一种上述钌配合物的治疗有效量的药物组合物，一种制备所述钌配合物的方法，以及一种使用至少一种所述钌配合物的治疗有效量治疗增殖生长相关疾病的方法。还声称了公式(II)的化合物。
• (η⁵-Cp*)Rh(III)/Ir(III) Complexes with Bis(chalcogenoethers) (E, E′ Ligands: E = S/Se; E′ = S/Se): Synthesis, Structure, and Applications in Catalytic Oppenauer-Type Oxidation and Transfer Hydrogenation
  作者：Om Prakash、Kamal Nayan Sharma、Hemant Joshi、Pancham L. Gupta、Ajai K. Singh

  DOI：10.1021/om401150s

  日期：2014.2.24

  Oppenauer-type oxidation of alcohols and transfer hydrogenation of ketones with 2-propanol. 3 and 6 were the most efficient in the two catalytic reactions (TON values up to 9.9 × 102 and 9.8 × 103, respectively) and were therefore investigated in detail. 3 is the first example of a Rh(III) species explored for Oppenauer-type oxidation. The catalysis appears to be homogeneous. In transfer hydrogenation it appears

  的空气和水分不敏感的半夹心络合物[（η 5 -Cp *）的Rh（大号）CL] [PF 6 ]（1 - 3）和[（η 5 -Cp *）IR（大号）CL] [ PF 6 ]（4 - 6）已经制备通过使大号= L1 - L3（1,2-双（苯硫基）乙烷（L1），1-（phenylseleno）-2-（苯硫基）乙烷（L2）和1， 1,2-双（phenylseleno）乙烷（L3））与[（η 5 -Cp *）的RhCl（μ-Cl）的] 2和[（η 5 -Cp *）的IrCl（μ-Cl）的] 2分别在室温下，接着用NH治疗4 PF 6。他们的HR-MS和1 H，13 C 1 1个H}，和77硒 1个H} NMR光谱通过身份验证它们。的单晶结构1 - 6已经通过X射线晶体学确定。配合物1 - 6已经探索了醇的催化奥盆诺尔型氧化和用2-丙醇酮的转移氢化。3和6是最有效的两个催化反应（TON值高达9.9×10
• Regioselective Markovnikov Hydrochalcogenation of Terminal Alkynes with Indium(III) Benzenechalcogenolates
  作者：Clovis Peppe、Liérson Borges de Castro、Melina de Azevedo Mello、Olga Soares do Rego Barros

  DOI：10.1055/s-2008-1072725

  日期：2008.5

  Indium(III) benzenechalcogenolates (chalcogen = sulfur and selenium) promote the rigorous Markovnikov hydrochalcogenation of terminal alkynes. The generality and limitations of the reaction with aminoalkynes leading to allylic amines bearing vinylic chalcogenide substituents are discussed.

  铟 (III) 苯硫属元素化物（硫属元素 = 硫和硒）促进末端炔烃的严格马尔科夫尼科夫加氢硫属元素化。讨论了与氨基炔烃反应生成带有乙烯基硫属化物取代基的烯丙胺的反应的一般性和局限性。
• Co-ordination chemistry of higher oxidation states. Part 41. Synthesis, spectroscopic and electrochemical studies of cationic ruthenium(III) Group 15 and 16 donor ligand complexes. Structure of trans-[Ru{C6F4(AsMe2)2-o}2Br2]BF4
  作者：Neil R. Champness、William Levason、Derek Pletcher、Michael Webster

  DOI：10.1039/dt9920003243

  日期：——

  The complexes trans-[Ru(L–L)2X2]BF4[X = Cl or Br; L–L = bidentate ligand including C6H4(PMe2)2-o, C6H4(AsMe2)2-o, C6F4(AsMe2)2-o, Me2PCH2CH2PMe2, Ph2PCH2CH2PPh2, Ph2AsCHCHAsPh2, C6H4(PPh2)2-o, C6F4(PPh2)2-o, MeSCH2CH2SMe, PhSCH2CH2SPh and PhSeCH2CH2SePh] have been prepared by nitric acid oxidation of the corresponding [Ru(L–L)2X2] in aqueous HBF4 and in other ways. The complexes have been characterised

  配合物反式-[Ru（L–L）2 X 2 ] BF 4 [X = Cl或Br; L–L =双齿配体，包括C 6 H 4（PMe 2）2 - o，C 6 H 4（AsMe 2）2 - o，C 6 F 4（AsMe 2）2 - o，Me 2 PCH 2 CH 2 PMe 2，苯2 PCH 2 CH 2 PPh2，Ph 2 AsCHCHAsPh 2，C 6 H 4（PPh 2） 2 - o，C 6 F 4（PPh 2） 2 - o，MeSCH 2 CH 2 SMe，PhSCH 2 CH 2 SPh和PhSeCH 2 CH 2 SePh]具有通过在HBF 4水溶液中硝酸氧化相应的[Ru（L–L） 2 X 2 ]制备以及其他方式。通过分析，IR和UV / VIS光谱，磁测量以及通过循环伏安法建立的Ru II –Ru III氧化还原电位来表征复合物。确定了反式-[Ru C 6 F 4（AsMe 2）2